Comment on: "Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?".
作者信息
Krebs-Brown Axel, Munafo Alain, Gaikwad Sumedh, Urgatz Bogumila, Castello-Bridoux Claire
机构信息
Merck KGaA, Darmstadt, Germany.
Merck Institute for Pharmacometrics (An Affiliate of Merck KGaA, Darmstadt, Germany), Lausanne, Switzerland.
出版信息
Clin Pharmacokinet. 2020 Feb;59(2):265-267. doi: 10.1007/s40262-019-00847-0.
Abstract
摘要
相似文献
1
Comment on: "Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?".
Clin Pharmacokinet. 2020 Feb;59(2):265-267. doi: 10.1007/s40262-019-00847-0.
2
Comment on: "Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?".
Clin Pharmacokinet. 2020 Feb;59(2):273-275. doi: 10.1007/s40262-019-00849-y.
3
Authors' Reply to Krebs-Brown et al. Comment on: "Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?".
Clin Pharmacokinet. 2020 Feb;59(2):269-271. doi: 10.1007/s40262-019-00848-z.
4
Authors' Reply to Nicolas: "Why Were More than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?".
Clin Pharmacokinet. 2020 Feb;59(2):277-279. doi: 10.1007/s40262-019-00851-4.
5
When Bioequivalence in Healthy Volunteers May not Translate to Bioequivalence in Patients: Differential Effects of Increased Gastric pH on the Pharmacokinetics of Levothyroxine Capsules and Tablets.
J Pharm Pharm Sci. 2015;18(5):844-55. doi: 10.18433/j36p5m.
6
Bioequivalence study of levothyroxine tablets compared to reference tablets and an oral solution.
Arzneimittelforschung. 2004;54(10):680-4. doi: 10.1055/s-0031-1297021.
7
Bioequivalence of two levothyroxine tablet formulations without and with mathematical adjustment for basal thyroxine levels in healthy Argentinian volunteers: a single-dose, randomized, open-label, crossover study.
Clin Ther. 2008 Nov;30(11):2015-23. doi: 10.1016/j.clinthera.2008.11.005.
8
New levothyroxine formulation meeting 95-105% specification over the whole shelf-life: results from two pharmacokinetic trials.
Curr Med Res Opin. 2017 Feb;33(2):169-174. doi: 10.1080/03007995.2016.1246434. Epub 2016 Oct 21.
9
Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?
Clin Pharmacokinet. 2020 Jan;59(1):1-5. doi: 10.1007/s40262-019-00812-x.
10
Bioequivalence of generic and brand-name levothyroxine products in the treatment of hypothyroidism.
JAMA. 1997 Apr 16;277(15):1205-13.
引用本文的文献
1
Comment on "Interchangeability between Generic and Reference Products: Limits of Average Bioequivalence Methodology".
Eur J Drug Metab Pharmacokinet. 2023 Mar;48(2):213-215. doi: 10.1007/s13318-022-00814-4. Epub 2023 Jan 21.
2
Pharmacokinetics and Generic Drug Switching: A Regulator's View.
Clin Pharmacokinet. 2020 Sep;59(9):1065-1069. doi: 10.1007/s40262-020-00909-8.
3
Authors' Reply to Krebs-Brown et al. Comment on: "Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?".
Clin Pharmacokinet. 2020 Feb;59(2):269-271. doi: 10.1007/s40262-019-00848-z.
本文引用的文献
1
Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?
Clin Pharmacokinet. 2020 Jan;59(1):1-5. doi: 10.1007/s40262-019-00812-x.
2
Authors' Reply to Castello-Bridoux et al.: "Comment on Levothyrox New and Old Formulations: Are they Switchable for Millions of Patients?".
Clin Pharmacokinet. 2019 Jul;58(7):973-975. doi: 10.1007/s40262-019-00786-w.
3
Comment on "Levothyrox New and Old Formulations: Are They Switchable for Millions of Patients?".
Clin Pharmacokinet. 2019 Jul;58(7):969-971. doi: 10.1007/s40262-019-00785-x.
4
Levothyrox New and Old Formulations: Are they Switchable for Millions of Patients?
Clin Pharmacokinet. 2019 Jul;58(7):827-833. doi: 10.1007/s40262-019-00747-3.
5
Why it is nonsensical to use retrospective power analyses to conduct a postmortem on your study.
J Clin Hypertens (Greenwich). 2018 Feb;20(2):408-410. doi: 10.1111/jch.13173. Epub 2017 Nov 23.
6
New levothyroxine formulation meeting 95-105% specification over the whole shelf-life: results from two pharmacokinetic trials.
Curr Med Res Opin. 2017 Feb;33(2):169-174. doi: 10.1080/03007995.2016.1246434. Epub 2016 Oct 21.
7
Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
Ann Pharmacother. 2009 Oct;43(10):1583-97. doi: 10.1345/aph.1M141. Epub 2009 Sep 23.
Zotero 插件